← Back to Search

Tyrosine Kinase Inhibitor

Osimertinib + Bevacizumab for Lung Cancer

DeKalb, IL

Phase 3

Recruiting

Led By Helena A Yu

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Patient must not have any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of registration, with the exception of alopecia and grade 2 prior platinum-therapy-related neuropathy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from randomization to documented disease progression per response evaluation criteria in solid tumors (recist) 1.1 or death from any cause, whichever occurs first, assessed up to 10 years

Awards & highlights

No Placebo-Only Group

Pivotal Trial

Summary

This trial is testing whether adding bevacizumab to osimertinib will help patients with EGFR-mutated, stage IIIB-IV non-small cell lung cancer live longer, as compared to osimertinib alone.

See full description

Who is the study for?

This trial is for adults with advanced non-small cell lung cancer (NSCLC) that has spread and have specific EGFR gene mutations. They should not have had previous treatments with EGFR TKI or anti-VEGF agents, no major heart issues, and must not be on strong CYP3A4 inducers. Patients can join if they've finished certain radiation therapies before starting the study drugs and if they don't have severe diseases or conditions that could affect their participation.Check my eligibility

What is being tested?

The trial is testing whether adding Bevacizumab to Osimertinib improves outcomes in patients compared to using Osimertinib alone. Both are cancer medications: Osimertinib targets a protein involved in tumor growth, while Bevacizumab may prevent tumors from creating new blood vessels needed for them to grow.See study design

What are the potential side effects?

Osimertinib might cause diarrhea, rash, dry skin, nail changes or mouth sores. Bevacizumab can lead to high blood pressure, bleeding problems, headaches or nosebleeds. When combined there's a risk of more intense side effects due to interactions between the two drugs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had hepatitis C but am cured, or I'm being treated with no detectable virus.

show original

Select...

I don't have severe side effects from previous treatments, except for hair loss or mild nerve pain.

show original

Select...

I have not received any systemic treatment for my metastatic disease.

show original

Select...

My lung cancer is non-squamous and confirmed by a pathology test.

show original

Select...

I don't have heart issues or family history that could affect my heart's rhythm.

show original

Select...

My cancer is advanced and cannot be treated with a combination of therapies.

show original

Select...

My cancer has a specific EGFR mutation, not the exon 20 insertion.

show original

Select...

I have not been treated with EGFR or anti-VEGF drugs.

show original

Select...

My hepatitis B virus is under control with treatment.

show original

Select...

My heart's electrical activity is normal, with no significant issues.

show original

Select...

I have never had lung conditions that caused scarring or needed steroids.

show original

Select...

I can take care of myself and am up and about more than half of my waking hours.

show original

Select...

My brain metastases are treated, stable, and I'm not on steroids after a specific waiting period post-treatment.

show original

Select...

I don't have bleeding from the lungs, heart disease, high blood pressure, kidney issues, or tumors in major blood vessels.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from randomization to documented disease progression per response evaluation criteria in solid tumors (recist) 1.1 or death from any cause, whichever occurs first, assessed up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from randomization to documented disease progression per response evaluation criteria in solid tumors (recist) 1.1 or death from any cause, whichever occurs first, assessed up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization to documented disease progression per response evaluation criteria in solid tumors (recist) 1.1 or death from any cause, whichever occurs first, assessed up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Progression-free survival (PFS)

Secondary study objectives

Best objective response rate

Central Nervous System

Incidence of adverse events

+2 more

Other study objectives

Circulating tumor deoxyribonucleic acid (ctDNA) clearance on study treatment

Mechanisms of resistance to AZD9291 (osimertinib) and AZD9291 (osimertinib) with bevacizumab first-line therapy through post-progression circulating tumor-derived deoxyribonucleic acid (ctDNA)

Side effects data

From 2024 Phase 2 trial • 155 Patients • NCT03133546

54%

Diarrhea

49%

Proteinuria

43%

Fatigue

42%

Hypertension

41%

Cough

36%

Rash acneiform

32%

Anorexia

29%

Pain

25%

Mucositis oral

25%

Constipation

24%

Headache

22%

Nausea

22%

Vomiting

21%

Dry skin

21%

Upper respiratory infection

21%

Epistaxis

20%

Platelet count decreased

17%

Dyspnea

17%

Paronychia

16%

Serum amylase increased

16%

Lipase increased

13%

Aspartate aminotransferase increased

13%

Alanine aminotransferase increased

13%

Back pain

13%

Edema limbs

13%

Electrocardiogram QT corrected interval prolonged

12%

Dizziness

12%

Ejection fraction decreased

12%

Non-cardiac chest pain

11%

Pruritus

Creatinine increased

Neutrophil count decreased

Abdominal pain

Sore throat

Anemia

Fever

Alkaline phosphatase increased

GGT increased

Rash maculo-papular

Urinary tract infection

Flu like symptoms

Hyponatremia

Arthralgia

White blood cell decreased

Lung infection

Dry eye

Blurred vision

Myalgia

Pleural effusion

Atrial fibrillation

Hypokalemia

Drug overdose

Pain in extremity

Dry mouth

Thromboembolic event

Heart failure

Fracture

Hypoglycemia

Pleural infection

Influenza

Depressed level of consciousness

Colitis

Influenza A

Ischemia cerebrovascular

Gastrointestinal pain

Hepatitis caused by COVID-19 infection

Anxiety

Bronchopulmonary hemorrhage

Gastric perforation

Enterocolitis infectious

Pneumothorax

Acute kidney injury

Osteonecrosis of jaw

Seizure

Pneumonitis

Bronchial infection

COVID-19 infection

100%

80%

60%

40%

20%

Study treatment Arm

Osimertinib Plus Bevacizumab

Osimertinib Alone

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm B (osimertinib, bevacizumab)Experimental Treatment7 Interventions

Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood and urine sample collection on study.

Group II: Arm A (osimertinib)Active Control6 Interventions

Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood and urine sample collection on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

2013

Completed Phase 4

~5540

Biospecimen Collection

2004

Completed Phase 3

~1810